with a 20.4% reduction in weight in the REDEFINE 1 study over 68 weeks that fell short of NovoNordisk's hope of a 25% loss. At the least, the new 7.2mg results point to scope for hiking the ...
Bagsværd, Denmark, 17 January 2025 – NovoNordisk today announced headline ... a statistically significant and superior weightloss at week 72 with semaglutide 7.2 mg versus placebo.